Navigation Links
FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Date:10/16/2007

ade 3/4: 54%) and leukopenia (Grade 3/4: 49%).

(Phase III, Combination Trial: -046) The randomized Phase III trial evaluated the efficacy and safety of IXEMPRA in combination with capecitabine in comparison with capecitabine as monotherapy. This trial included 752 patients who were previously treated with anthracyclines and taxanes, and whose tumors had demonstrated prior resistance to these therapies. Anthracycline resistance is defined as progression while on therapy or within six months in the adjuvant setting, or three months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or four months in the metastatic setting. Evaluation of the primary endpoint demonstrated that IXEMPRA in combination with capecitabine resulted in a statistically significant improvement in progression-free survival compared to capecitabine monotherapy - median 5.7 (95% CI, 4.8-6.7) vs. 4.1 months (95% CI, 3.1-4.3); P<0.0001, Hazard ratio=0.69 (95% CI, 0.58-0.83).

Treatment-related non-hematological adverse events (greater than or equal to 20%) reported in patients treated with IXEMPRA in combination with capecitabine included: peripheral sensory neuropathy 65% (Grade 3/4: 21%), palmar-plantar erythrodysesthesia (hand-foot) syndrome 64% (Grade 3/4: 18%), fatigue/asthenia 60% (Grade 3/4: 16%), nausea 53% (Grade 3/4: 3%), diarrhea 44% (Grade 3/4: 6%), vomiting 39% (Grade 3/4: 4%), myalgia/arthralgia 39% (Grade 3/4: 8%), anorexia 34% (Grade 3/4: 3%), stomatitis/mucositis 31% (Grade 3/4: 4%), alopecia 31% (Grade 3/4: 0%), abdominal pain 24% (Grade 3/4: 2%), nail disorder 24% (Grade 3/4: 2%), musculoskeletal pain 23% (Grade 3/4: 2%), and constipation 22% (Grade 3/4: 0%). Treatment-related hematological adverse events (greater than or equal to 20%) reported in patients treated with IXEMPRA in combination with capecitabine included: neutropenia (Grade 3/4: 68%) and leukopenia (Grade 3/4: 57%).

Compa
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. Analog people in the Digital Revolution, part II
9. Analog people in the digital revolution
10. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
11. Improve Recovery and Reproducibility with Pre-Treatment of Analytical TSK-GEL G3000SWXL Size Exclusion Columns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014  Biocom, the association representing the ... 9 th Annual National Health Information Technology Week, ... in improving our health care system. ... the world,s most vibrant hubs for health IT and ... to genomic testing to remote patient monitoring," said ...
(Date:9/16/2014)... From cell phones to cars and flashlights, batteries ... and technology companies constantly are seeking ways to ... first time using a water-based solution, researchers at ... and more efficient nuclear battery that could be ... energy source in automobiles and also in complicated ...
(Date:9/16/2014)... BlueInGreen® , a water quality ... delivering dissolved gases into liquids, announced the addition ... manufacturer’s representative firm to its sales network. H2Flow ... water and wastewater applications in the Canadian provinces ... in 1992 and serves Quebec and Ontario markets ...
(Date:9/16/2014)... , Sept. 16, 2014  Donald Fresne, President and ... of Stephan Vagner , PhD to its Scientific Advisory ... of Toulouse, France , performed research at ... , and at Inserm, the French institute of health and ... works both at the Curie Institute, Orsay, France ...
Breaking Biology Technology:Biocom Recognizes National Health IT Week 2BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2
... , , , ... RA (TM), a new online talk show hosted by award-winning journalist and ... , , To view the Multimedia News Release, go ... ) , , New Way RA ...
... , SCOTTSDALE, Ariz., July 29 ... subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBS), ... is both active on oral administration and provides therapeutic effects ... Preliminary analysis of ongoing bioavailability studies in rats ...
... , , SOUTH SAN FRANCISCO, Calif., ... reported financial results for the second quarter ended June 30, 2009. , ... was $3.5 million, with a net loss of $22.9 million, including non-cash ... from operations was $1.9 million for the second quarter and $10.2 million ...
Cached Biology Technology:Video: New Way RA(TM) Talk Show Premieres Online for People Living With Rheumatoid Arthritis (RA) 2Video: New Way RA(TM) Talk Show Premieres Online for People Living With Rheumatoid Arthritis (RA) 3Video: New Way RA(TM) Talk Show Premieres Online for People Living With Rheumatoid Arthritis (RA) 4ImmuneRegen BioSciences Confirms Homspera's Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration 2ImmuneRegen BioSciences Confirms Homspera's Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration 3Sunesis Reports Financial Results for the Second Quarter 2009 2Sunesis Reports Financial Results for the Second Quarter 2009 3Sunesis Reports Financial Results for the Second Quarter 2009 4Sunesis Reports Financial Results for the Second Quarter 2009 5Sunesis Reports Financial Results for the Second Quarter 2009 6Sunesis Reports Financial Results for the Second Quarter 2009 7Sunesis Reports Financial Results for the Second Quarter 2009 8Sunesis Reports Financial Results for the Second Quarter 2009 9Sunesis Reports Financial Results for the Second Quarter 2009 10Sunesis Reports Financial Results for the Second Quarter 2009 11
(Date:9/16/2014)... has its own bacterial identity. That,s the conclusion of ... who studied the genetic fingerprints of bacteria on 57 ... "This study demonstrates for the first time that host ... strategies possess very different microbial communities on their leaves," ... researcher in the UO,s Institute of Ecology and Evolution ...
(Date:9/16/2014)... The fall marks a new school year, a new ... International Space Station. In September, SpaceX,s Dragon spacecraft is ... supplies and investigations as part of the company,s fourth ... cargo will be the third suite of research investigations ... in Space (CASIS). With the role of managing the ...
(Date:9/16/2014)... years after the Hesperides vessel returned to Spain culminating ... have an increasingly clear picture of how the global ... the input of pollutants from the atmosphere is not ... most remote areas of the planet, and it is ... are presented this week in CSIC Residence for Researchers ...
Breaking Biology News(10 mins):Microbiome research shows each tree species has a unique bacterial identity 2CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
... CORVALLIS, Ore. The soils in large areas of the ... America, have been drying up in the past decade, a ... ever examine "evapotranspiration" on a global basis. Most climate ... water from the land to the atmosphere, would increase with ...
... 9, 2010 Help may be on the way for ... the invasion of stink bugs. Scientists have reported a key ... stinkbugs, which are emerging as a major nuisance to homeowners ... a natural substance in a fungus that infects a common ...
... have reported direct evidence that taking up smoking results in ... results were reported at the 35th Congress of the European ... link between smoking and cancer has been established for decades, ... Institute of Cancer Studies, Birmingham, who presented the results. Smoking ...
Cached Biology News:Land 'evapotranspiration' taking unexpected turn: huge parts of world are drying up 2Land 'evapotranspiration' taking unexpected turn: huge parts of world are drying up 3Progress toward first commercial repellent for East Coast's stinker 2Study reveals cancer-linked epigenetic effects of smoking 2
... identification Service includes 1. Scanning of ... 3. High-sensitive tryptic in-gel digestion and ... for MALDI-MS 5. Acquisition of PMF ... (Bruker ultraflex TOF/TOF) 6. Acquisition of ...
Each Yeast-GFP clone represents an individual S. cerevisiae strain containing an open reading frame with a C-terminal Aequorea Victoria GFP (S65T) fusion tag....
... number is a new product number, ... number. If showing no availability yet, ... number (R4276) or contact customer service ... (expanded surface, easy grip) ...
... stored within neurons in vesicles called ... the synaptic bouton. Synaptosomes may ... from other cellular debris. Abnormalites in ... many pathological condtions. Conditions of ...
Biology Products: